26.00
-0.06 (-0.23%)
| Previous Close | 26.06 |
| Open | 25.02 |
| Volume | 1,825,420 |
| Avg. Volume (3M) | 1,267,798 |
| Market Cap | 3,270,102,272 |
| Price / Sales | 11.33 |
| Price / Book | 5.19 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Profit Margin | -277.30% |
| Operating Margin (TTM) | -435.71% |
| Diluted EPS (TTM) | -4.23 |
| Quarterly Revenue Growth (YOY) | -80.70% |
| Total Debt/Equity (MRQ) | 15.25% |
| Current Ratio (MRQ) | 5.37 |
| Operating Cash Flow (TTM) | -300.00 M |
| Levered Free Cash Flow (TTM) | -174.00 M |
| Return on Assets (TTM) | -22.25% |
| Return on Equity (TTM) | -63.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Arcus Biosciences, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.5 |
| Average | -0.80 |
|
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 34.93% |
| % Held by Institutions | 64.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2025 | 31,424,760 |
| Siren, L.L.C. | 31 Dec 2025 | 3,007,077 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 49.00 (Leerink Partners, 88.46%) | Buy |
| Median | 45.00 (73.08%) | |
| Low | 32.00 (HC Wainwright & Co., 23.08%) | Buy |
| Average | 42.00 (61.54%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 23.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 05 Mar 2026 | 45.00 (73.08%) | Buy | 22.21 |
| HC Wainwright & Co. | 02 Mar 2026 | 32.00 (23.08%) | Buy | 23.94 |
| Leerink Partners | 02 Mar 2026 | 49.00 (88.46%) | Buy | 23.94 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GOELTZ II ROBERT C. | - | 24.86 | -7,763 | -192,988 |
| Aggregate Net Quantity | -7,763 | |||
| Aggregate Net Value ($) | -192,988 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 24.86 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GOELTZ II ROBERT C. | Officer | 11 May 2026 | Automatic sell (-) | 7,763 | 24.86 | 192,988 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |